Regulus Therapeutics (NASDAQ:RGLS) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.18) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.07, Fidelity Earnings reports. Regulus Therapeutics had a negative net margin of 83,538.89% and a negative return on equity of 205.48%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million.
Shares of RGLS traded down $0.11 during mid-day trading on Friday, hitting $1.66. The company’s stock had a trading volume of 3,075 shares, compared to its average volume of 1,192,284. The stock has a market capitalization of $17.46 million, a P/E ratio of -0.14 and a beta of 1.78. Regulus Therapeutics has a fifty-two week low of $1.71 and a fifty-two week high of $17.28.
A number of analysts have commented on RGLS shares. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 12th. ValuEngine upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Wedbush restated a “hold” rating and set a $1.00 price target on shares of Regulus Therapeutics in a research report on Friday, August 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research report on Friday, August 10th. Eight research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Regulus Therapeutics has an average rating of “Hold” and a consensus price target of $1.42.
ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (RGLS) Posts Earnings Results” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://sportsperspectives.com/2018/11/09/regulus-therapeutics-rgls-posts-earnings-results.html.
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Further Reading: Book Value Per Share – BVPS
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.